Financial distress among breast cancer survivors

Abstract

Aims: there has been an increasing awareness of the potential for oncology care to result in long-term financial burdens and financial toxicity. Patients who report cancer-related financial problems or high costs are more likely to forgo or delay prescription medications and medical care. Materials and Methods: we examined financial distress using data from a survey of 164 breast cancer survivors who had completed primary therapy for the disease. Key Findings: among respondents, 8.6% (13 of 151) reported that “being less able to provide for the financial needs of their family” was as a severe problem; 14.4% (22 of 153) reported “difficulty in meeting medical expenses” was a severe problem; and 8.4% (13 of 154) reported that “no money for cost of or co-payment for medical visits” was a severe problem. About 8.4% (13 of 154) of the respondents reported that “no money for cost of or co-payment for medicine” was a severe problem. In logistic regression analysis, younger age and lower household income were significant predictors of financial distress. In multiple linear regression analysis, younger age and lower household income were significant predictors of financial distress. Significance: financial toxicity remains a major issue in breast cancer care. Efforts are needed to ensure patients experiencing high levels of financial toxicity are able to access recommended care. In addition, patients should talk with their providers about the costs of oncology care and about opportunities to reduce costs while maintaining high quality of care.

Evolving Perceptions, Utilization, and Real-World Implementation Experiences of Oncology Monoclonal Antibody Biosimilars in the USA: Perspectives from Both Payers and Physicians

“…Some physicians in our study agreed that the lower cost of biosimilars would likely result in improved access to cancer treatment with biologics. It is well-established that cancer-related financial toxicity (CRFT) is associated with an increased risk for medical noncompliance and delayed prescription refills and critical care, which can negatively affect clinical outcomes [34][35][36]. The introduction of biosimilars may help mitigate CRFT in patients with cancer [37].…”

The Association between The Patient’s Age Groups with Stage, Grading, and Molecular Subtype of Breast Cancer

“…4 Breast cancer is one of the major health burdens in Indonesia. The burdens are different exposures to risk factors, economic settings, lifestyles, access to care and screening, 5 delay in seeking help and non-adherence 6 , financial toxicity, 7,8 , and Social Insurance Administration Organization reported that from 1,308,061 inpatient cancer cases treated in 2016, a total of 2.2 trillion rupiahs was spent, amounting to $486,960,633 in the US dollars (purchasing power…”

Retrospection and prospect of Current Cancer Reports (CCR)

“…Firstly, in view of the fact that there is no good strategy to cure cancer completely at present, the post-operative care and rehabilitation of cancer patients, the burden of patients' families and the social care measures for cancer patients have undoubtedly become the forefront and hotspot of contemporary cancer prevention and treatment research. Coughlin et al shared their series of original explorations on the related topics in these respects [1][2][3][4][5][6]. Mori et al explored the interactions between HIF and COX-2 with chemotherapeutic agents under normoxia and hypoxia with breast cancer cell MDA-MB-231 and SUM-149 as in vitro cell models under the background of 5-FU treatment, tried finding the potentials of COX-2 inhibitors for enhancing the therapeutic effects of 5-FU on triple negative breast cancer (TNBC), a subgroup of breast cancer lacking the expression of estrogen and progesterone receptors as well as HER2 [7].…”